People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2013 |
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2009 |
| Chimeros Inc | — | Other Health Care | Pre-Seed | $4.1M | $11.6M | 2009 |
John Mendlein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Mendlein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Noubar Afeyan | 2 | 9 |
| Lorence Kim | 2 | 5 |
| Lee Babiss | 2 | 5 |
| PETER HUTT | 2 | 4 |
| Stephane Bancel | 2 | 4 |
| Henri Termeer | 2 | 3 |
| Robert Nelsen | 1 | 22 |
| Bryan Roberts | 1 | 18 |
| Michael Lee | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Frank Foster | 1 | 12 |
| Robert Epstein | 1 | 8 |
| Carl Weissman | 1 | 8 |
| Bryan E. Roberts | 1 | 6 |
| Ilan Zipkin | 1 | 6 |
| Robert Carpenter | 1 | 5 |
| PAUL Grayson | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| Stephen Watkins | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.